269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群 Pyogenic arthritis Clinical trials / Disease details


臨床試験数 : 24 薬物数 : 30 - (DrugBank : 12) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 105

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04901325
(ClinicalTrials.gov)
September 29, 202117/5/2021Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)Pyoderma Gangrenosum;Skin Diseases;Wound Heal;Pyoderma;Skin UlcerDrug: BaricitinibOregon Health and Science UniversityNULLRecruiting18 Years99 YearsAll20Phase 2United States
2NCT05120726
(ClinicalTrials.gov)
June 2, 202111/9/2021A Novel Therapeutic Treatment of Pyoderma GangrenosumA Novel Therapeutic Treatment of Pyoderma GangrenosumPyoderma GangrenosumBiological: Dehydrated human amnion/chorion membraneLouisiana State University Health Sciences Center in New OrleansNULLRecruiting18 YearsN/AAll20Phase 4United States
3NCT04895566
(ClinicalTrials.gov)
May 24, 202117/5/2021Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent PyodermaPhase 0/1 Topical Application of the Monoclonal Antibody (Mab) sB24M in Patients With Severe PyodermaPyoderma;Pyoderma Gangrenosum;Pyoderma Vegetans;Pyoderma Gangrenosum Surrounding Surgical StomaBiological: Monoclonal antibody (Mab) sB24MSWISS BIOPHARMA MED GmbHNULLActive, not recruiting21 Years80 YearsAll10Early Phase 1Belarus;Latvia
4NCT04274166
(ClinicalTrials.gov)
May 202112/2/2020Secukinumab for the Inflammatory Phase of Pyoderma GangrenosumThe Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma GangrenosumPyoderma GangrenosumDrug: secukinumab 150 mg (2 injections per doseWake Forest University Health SciencesNovartisWithdrawn18 Years75 YearsAll0Phase 2United States
5EUCTR2020-003273-21-PL
(EUCTR)
09/11/202008/09/2020NAOpen label exploratory phase IIa trial to investigate the safety and efficacy of IFX-1 in treating subjects with Pyoderma Gangrenosum (OPTIMA). - Exploratory study of IFX-1 in Subjects with Pyoderma Gangrenosum Pyoderma gangrenosum
MedDRA version: 20.0;Level: PT;Classification code 10037635;Term: Pyoderma gangrenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: IFX-1
Other descriptive name: Anti-(complement C5a) IgG4 chimeric monoclonal antibody
Product Name: IFX-1
Other descriptive name: Anti-(complement C5a) IgG4 chimeric monoclonal antibody
InflaRx GmbHNULLNot RecruitingFemale: yes
Male: yes
18Phase 2United States;Poland
6NCT03971643
(ClinicalTrials.gov)
May 16, 201928/5/2019Exploratory Study of IFX-1 in Subjects With Pyoderma GangrenosumOpen Label Exploratory Phase 2a Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Subjects With Pyoderma Gangrenosum (Optima)Pyoderma GangrenosumDrug: IFX-1InflaRx GmbHInnovaderm Research Inc.Completed18 YearsN/AAll19Phase 2United States;Canada;Poland
7NCT03311464
(ClinicalTrials.gov)
October 27, 201712/10/2017A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in JapanA Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in JapanPyoderma GangrenosumDrug: adalimumabAbbVieNULLCompleted18 YearsN/AAll22Phase 3Japan
8NCT03072953
(ClinicalTrials.gov)
June 7, 201717/2/2017Efficacy and Safety of APD334 in Patients With Pyoderma GangrenosumA Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (APD334) in Patients With Pyoderma GangrenosumPyoderma GangrenosumDrug: APD334Arena PharmaceuticalsNULLTerminated18 Years80 YearsAll2Phase 2Australia;New Zealand
9NCT03137160
(ClinicalTrials.gov)
May 4, 201727/4/2017An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma GangrenosumAn Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma GangrenosumPyoderma GangrenosumBiological: IxekizumabOhio State UniversityEli Lilly and CompanyCompleted18 YearsN/AAll5Phase 2United States
10NCT02733094
(ClinicalTrials.gov)
April 201628/3/2016Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma GangrenosumSingle-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma GangrenosumPyoderma GangrenosumDrug: SecukinumabTechnische Universität MünchenNovartisActive, not recruiting18 Years75 YearsAll8Phase 1/Phase 2Germany
11EUCTR2015-000762-65-DE
(EUCTR)
09/07/201525/06/2015Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosuSingle-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosum Pyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of the skin. Treatment of PG is difficult. Patients suffer from long hospitalization, pain and reduced life quality. New therapeutic strategies are needed. Immunohistological staining show a high amount of IL-17 in PG. IL-17+ immune cells were located in proximity to cellular damage, indicating an involvement in the pathogenesis. Targeting IL-17 with neutralizing IL-17 antibodies seems promising.
MedDRA version: 20.0;Level: PT;Classification code 10037635;Term: Pyoderma gangrenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: Cosentyx®
Product Name: Cosentyx
Product Code: EU/1/14/980/002; EU/1/14/980/003
Technische Universität München, School of Medicine, represented by DeanNULLNot RecruitingFemale: yes
Male: yes
7Phase 2;Phase 3Germany
12NCT02366260
(ClinicalTrials.gov)
February 201511/2/2015An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumA Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumPyoderma GangrenosumDrug: Gevokizumab;Drug: PlaceboMedDerm AssociatesXOMA (US) LLCRecruiting18 YearsN/ABoth5Phase 3United States
13NCT02326740
(ClinicalTrials.gov)
December 201422/12/2014An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumA Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumPyoderma GangrenosumDrug: gevokizumab;Drug: Placebo;Drug: gevokizumab open-labelXOMA (US) LLCNULLTerminated18 YearsN/ABoth9Phase 3United States;Australia;Canada
14NCT02315417
(ClinicalTrials.gov)
November 20145/12/2014An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumA Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumPyoderma GangrenosumDrug: gevokizumab;Drug: Placebo;Drug: gevokizumab open-labelXOMA (US) LLCNULLTerminated18 YearsN/ABoth16Phase 3United States
15NCT02318914
(ClinicalTrials.gov)
November 20148/12/2014A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma GangrenosumA 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma GangrenosumPyoderma GangrenosumDrug: gevokizumabXOMA (US) LLCNULLTerminated18 YearsN/ABoth15Phase 3United States;Australia;Canada
16NCT01965613
(ClinicalTrials.gov)
January 31, 201415/10/2013A Phase II Open Label Study of Xilonix in Subjects With Pyoderma GangrenosumA Phase II Open Label Study of Xilonix in Subjects With Pyoderma GangrenosumPyoderma GangrenosumBiological: XilonixJanssen Research & Development, LLCNULLCompleted18 YearsN/AAll10Phase 2United States
17NCT01882504
(ClinicalTrials.gov)
May 201317/6/2013Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma GangrenosumAn Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma GangrenosumPyoderma GangrenosumDrug: gevokizumabXOMA (US) LLCNULLCompleted18 YearsN/ABoth8Phase 2United States
18EUCTR2011-002920-41-DE
(EUCTR)
04/01/201224/08/2011Stelara® (Ustekinumab) treatment in Patients with Pyoderma gangrenosumOpen-label Trial of Stelara® (Ustekinumab) In Patients with Pyoderma gangrenosum – an open, non-placebo controlled pilot study with 10 patients. - SPG-Trial Patients with a clinical diagnosis of Pyoderma gangrenosum
MedDRA version: 14.1;Level: LLT;Classification code 10037634;Term: Pyoderma gangenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
Trade Name: Stelara
Product Name: Ustekinumab
Other descriptive name: USTEKINUMAB
University Hospital TübingenNULLNot RecruitingFemale: yes
Male: yes
Germany
19NCT01302795
(ClinicalTrials.gov)
February 201117/2/2011Canakinumab for Pyoderma GangrenosumA Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma GangrenosumPyoderma GangrenosumDrug: CanakinumabUniversity of ZurichNULLCompleted18 Years99 YearsBoth5Phase 2Switzerland
20EUCTR2008-008291-14-IE
(EUCTR)
31/03/201008/10/2009Study of treatments in Pyoderma Gangrenosum patients - STOP GAPStudy of treatments in Pyoderma Gangrenosum patients - STOP GAP pyoderma gangrenosum
MedDRA version: 9.1;Level: LLT;Classification code 10037634;Term: Pyoderma gangenosum
MedDRA version: 9.1;Classification code 10037635;Term: Pyoderma gangrenosum
Trade Name: Neoral soft gelatin capsules
INN or Proposed INN: CICLOSPORIN
Trade Name: Neoral Oral Solution
INN or Proposed INN: CICLOSPORIN
Product Name: Prednisolone
INN or Proposed INN: PREDNISOLONE
Product Name: Prednisolone
INN or Proposed INN: PREDNISOLONE
Product Name: Prednisolone
INN or Proposed INN: PREDNISOLONE
Nottingham University Hospitals NHS TrustNULLNot RecruitingFemale: yes
Male: yes
United Kingdom;Ireland
21EUCTR2008-008291-14-GB
(EUCTR)
14/05/200922/05/2009Study of treatments in Pyoderma Gangrenosum patients - STOP GAPStudy of treatments in Pyoderma Gangrenosum patients - STOP GAP pyoderma gangrenosum
MedDRA version: 14.0;Level: LLT;Classification code 10037634;Term: Pyoderma gangenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders
MedDRA version: 14.0;Level: PT;Classification code 10037635;Term: Pyoderma gangrenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders
Trade Name: Neoral soft gelatin capsules
INN or Proposed INN: CICLOSPORIN
Trade Name: Neoral Oral Solution
INN or Proposed INN: CICLOSPORIN
Product Name: Prednisolone
INN or Proposed INN: PREDNISOLONE
Product Name: Prednisolone
INN or Proposed INN: PREDNISOLONE
Product Name: Prednisolone
INN or Proposed INN: PREDNISOLONE
Nottingham University Hospitals NHS TrustNULLNot Recruiting Female: yes
Male: yes
140 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesIreland;United Kingdom
22NCT00730717
(ClinicalTrials.gov)
May 20094/8/2008Safety and Efficacy Study of Humira in Treatment of Pyoderma GangrenosumMulti Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma GangrenosumPyoderma GangrenosumDrug: HumiraWright State UniversityStanford University;Wake Forest University Health SciencesWithdrawn18 YearsN/AAll0Phase 2United States
23NCT00791557
(ClinicalTrials.gov)
October 200813/11/2008Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel DiseaseAn Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma GangrenosumPyoderma Gangrenosum;Crohn's Disease;Ulcerative Colitis;Inflammatory Bowel DiseaseDrug: InfliximabUniversity Hospitals Cleveland Medical CenterCentocor, Inc.Completed18 Years75 YearsAll2N/AUnited States
24NCT00690846
(ClinicalTrials.gov)
July 20072/6/2008Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma GangrenosumA Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37)Pyoderma GangrenosumDrug: adalimumabWake Forest University Health SciencesNULLWithdrawn18 YearsN/AAll0Phase 2United States